206 related articles for article (PubMed ID: 29391351)
1. T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors.
Hu J; Sun C; Bernatchez C; Xia X; Hwu P; Dotti G; Li S
Clin Cancer Res; 2018 Jun; 24(12):2920-2934. PubMed ID: 29391351
[No Abstract] [Full Text] [Related]
2. CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo.
Wennerberg E; Kremer V; Childs R; Lundqvist A
Cancer Immunol Immunother; 2015 Feb; 64(2):225-35. PubMed ID: 25344904
[TBL] [Abstract][Full Text] [Related]
3. B7H4 expression in tumor cells impairs CD8 T cell responses and tumor immunity.
Zhou L; Ruan M; Liu Y; Zhu Y; Fu D; Wu K; Zhang Q
Cancer Immunol Immunother; 2020 Feb; 69(2):163-174. PubMed ID: 31848656
[TBL] [Abstract][Full Text] [Related]
4. Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication.
Quezada SA; Peggs KS; Simpson TR; Allison JP
Immunol Rev; 2011 May; 241(1):104-18. PubMed ID: 21488893
[TBL] [Abstract][Full Text] [Related]
5. IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of TÂ cell engager immunotherapy.
Lee KJ; Choi D; Tae N; Song HW; Kang YW; Lee M; Moon D; Oh Y; Park S; Kim JH; Jeong S; Yang J; Park U; Hong DH; Byun MS; Park SH; Sohn J; Park Y; Im SK; Choi SS; Kim DH; Lee SW
Cell Rep Med; 2024 May; 5(5):101567. PubMed ID: 38744277
[TBL] [Abstract][Full Text] [Related]
6. Pathogen boosted adoptive cell transfer immunotherapy to treat solid tumors.
Xin G; Schauder DM; Jing W; Jiang A; Joshi NS; Johnson B; Cui W
Proc Natl Acad Sci U S A; 2017 Jan; 114(4):740-745. PubMed ID: 28069963
[TBL] [Abstract][Full Text] [Related]
7. High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance.
Saeed MA; Peng B; Kim K; Rawat K; Kuehm LM; Siegel ZR; Borkowski A; Habib N; Van Tine B; Sheikh N; Tuyen V; Thorek DLJ; Fehniger TA; Pachynski RK
Cancer Immunol Res; 2024 May; 12(5):559-574. PubMed ID: 38407894
[TBL] [Abstract][Full Text] [Related]
8. Cancer immunity by tissue-resident type 1 innate lymphoid cells and killer innate-like T cells.
Zhang J; Li AM; Kansler ER; Li MO
Immunol Rev; 2024 May; 323(1):150-163. PubMed ID: 38506480
[TBL] [Abstract][Full Text] [Related]
9. Tumor-specific T-bodies: towards clinical application.
Eshhar Z
Cancer Immunol Immunother; 1997; 45(3-4):131-6. PubMed ID: 9435856
[TBL] [Abstract][Full Text] [Related]
10. Rank aggregation of independent genetic screen results highlights new strategies for adoptive cellular transfer therapy of cancer.
Vianzon VV; Hanson RM; Garg I; Joseph GJ; Rogers LM
Front Immunol; 2023; 14():1235131. PubMed ID: 38143765
[TBL] [Abstract][Full Text] [Related]
11. Low-dose radiotherapy synergizes with iRGD-antiCD3-modified T cells by facilitating T cell infiltration.
Zhou S; Zhu M; Wei X; Mu P; Shen L; Wang Y; Wan J; Zhang H; Xia F; Zhang Z
Radiother Oncol; 2024 May; 194():110213. PubMed ID: 38458258
[TBL] [Abstract][Full Text] [Related]
12. Chemokine Receptors and Exercise to Tackle the Inadequacy of T Cell Homing to the Tumor Site.
Idorn M; Thor Straten P
Cells; 2018 Aug; 7(8):. PubMed ID: 30126117
[TBL] [Abstract][Full Text] [Related]
13. XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies.
Patel E; Malkova NV; Crowe D; Pederzoli-Ribeil M; Fantini D; Fanny M; Madala HR; Jenkins KA; Yerov O; Greene J; Guzman W; O'Toole C; Taylor J; O'Donnell RK; Johnson P; Lanter BB; Ames B; Chen J; Vu S; Wu HJ; Cantin S; McLaughlin M; Hsiao YS; Tomar DS; Rozenfeld R; Thiruneelakantapillai L; O'Hagan RC; Nicholson B; O'Neil J; Bialucha CU
Mol Cancer Ther; 2024 Apr; 23(4):421-435. PubMed ID: 38030380
[TBL] [Abstract][Full Text] [Related]
14. The mosquito effect: regulatory and effector T cells acquire cytoplasmic material from tumor cells through intercellular transfer.
Hioki KA; Ryan DJ; Thesmar I; Lynch AC; Pobezinsky LA; Pobezinskaya EL
Front Immunol; 2023; 14():1272918. PubMed ID: 38179041
[TBL] [Abstract][Full Text] [Related]
15. Beyond the CAR T Cells: TIL Therapy for Solid Tumors.
Singh R
Immune Netw; 2024 Apr; 24(2):e16. PubMed ID: 38725673
[No Abstract] [Full Text] [Related]
16. Desensitized chimeric antigen receptor T cells selectively recognize target cells with enhanced antigen expression.
Han C; Sim SJ; Kim SH; Singh R; Hwang S; Kim YI; Park SH; Kim KH; Lee DG; Oh HS; Lee S; Kim YH; Choi BK; Kwon BS
Nat Commun; 2018 Feb; 9(1):468. PubMed ID: 29391449
[TBL] [Abstract][Full Text] [Related]
17. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity.
Davenport AJ; Cross RS; Watson KA; Liao Y; Shi W; Prince HM; Beavis PA; Trapani JA; Kershaw MH; Ritchie DS; Darcy PK; Neeson PJ; Jenkins MR
Proc Natl Acad Sci U S A; 2018 Feb; 115(9):E2068-E2076. PubMed ID: 29440406
[TBL] [Abstract][Full Text] [Related]
19. Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines.
Moon EK; Wang LS; Bekdache K; Lynn RC; Lo A; Thorne SH; Albelda SM
Oncoimmunology; 2018; 7(3):e1395997. PubMed ID: 29399394
[TBL] [Abstract][Full Text] [Related]
20. Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines.
Raikar SS; Fleischer LC; Moot R; Fedanov A; Paik NY; Knight KA; Doering CB; Spencer HT
Oncoimmunology; 2018; 7(3):e1407898. PubMed ID: 29399409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
